Oliver Herd

Biography

Constance Höfer is a drug development professional with more than 15 years of international experience in academic, industrial and regulatory environments. After a BSc (1990, Genetics & Cell Biology, University of Manchester), and a PhD (1995, Pharmacology, Pharmacogenetics Institute Prof JR Idle, Newcastle, UK), she held positions at the Norwegian Medicines Authority, the Norwegian Institutes of Health and the University of Cambridge/Papworth Hospital in regulatory and research capacities. Since 2001, she worked in senior drug discovery and development capacities at international biotech and Pharma companies (Celltech UK, Solvay Pharmaceuticals, Merck KGaA) and was VP Drug development at Medigene AG, where she was instrumental in the recovery of a stalled clinical stage program. She joined Priaxon AG as CDO in January 2014, where she secured funds to change strategy and structure towards an R&D organization pursuing novel PPI/PDI targets, and was responsible for the initiation of the ras and myc projects. In August 2015, she was appointed COO and is the sole manager of Priaxon AG. Since 2006, Dr Höfer runs an independent drug development consultancy, where she was involved in the transition from preclinical to clinical development of more than 10 projects (national and international Biotech and Pharma) including NCEs, NBEs and drug delivery devices. She has also given numerous invited lectures, seminars and company workshops on drug development strategies.

Research Interest

Pharmacology, Pharmacogenetics